Mode
Text Size
Log in / Sign up
N/A Completed N=223 Randomized Triple-blind Treatment

Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee

Osteoarthritis of Knee
Source: ClinicalTrials.gov NCT00790985 ↗
Enrolled (actual)
223
Serious AEs
0.0%
Results posted
Nov 2022
Primary outcomePrimary: Western Ontario and McMaster Universities Arthritis (WOMAC) Composite Score: Percent Change From Baseline to Week 12. — 85.75; 69.97 percentage of change

Summary

To compare flavocoxid with naproxen for patients with moderate to severe osteoarthritis of the knee.

Outcome Measures

OutcomeResultp-value
PRIMARY
Western Ontario and McMaster Universities Arthritis (WOMAC) Composite Score: Percent Change From Baseline to Week 12.
85.75; 69.97

Eligibility Criteria

Inclusion Criteria

  • Willing and able to read and understand informed consent and questionnaires in English.
  • Adults of either gender age 35-75 years, in general good health.
  • Established X-ray diagnosis of osteoarthritis of at least one knee.
  • Taken NSAID including COX-2 (cyclo-oxygenase-2) inhibitor in full therapeutic dose for at least one month prior to screening.
  • Able and will to discontinue osteoarthritis medications until flare criteria met.
  • BMI 2.0 or nephrotic syndrome with 24 hour protein excretion >1000mg.
  • Intra-articular injection of any hyaluronic acid preparation in the target knee joint within 4 months of baseline visit.
  • Intra-articular injection of a corticosteroid in the target knee joint within 2 months of the baseline visit.
  • BMI>45
  • History of allergic reaction to flavonoid or flavan containing foods or products (example: red wine, colored fruits and vegetable, brazil nuts, tea, natto)
  • History of allergy to aspirin, naproxen or other NSAID
  • History of substance abuse including alcohol, or any psychiatric condition that may impair the subject's ability to comply with the study requirements.
  • Any medical condition that, in the opinion of the investigator, might put the subject at undue risk or might interfere with the subject's ability to participate in the study.
  • Participation in another clinical trial within 30 days or 7 half lives of the study agent, whichever is longer, of the screening visit.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00790985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search